Evidence map›Paper›PMID 30488278›Full record

SynthesisPathology oncology research : POR2019

Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis.

Gongping Sun, Jin Meng, He Duan, Dewei Zhang, Yuanxin Tang

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Pathology oncology research : POR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.8field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Novel Liquid Biopsy in Gastrointestinal Cancers.Journal of gastroenterology and hepatology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Methylated Septin9 (mCancer research communications · 2022
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Gongping SunDepartment of the Third general surgery, The Fourth Affiliated Hospital of the China Medical University, No. 4 Chongshan Road, Shenyang, 110032, China.
Jin MengShenyang Anorectal Hospital, No. 9 North of Nanjing Street, Heping District, Shenyang, 110000, China.
He DuanDepartment of the Third general surgery, The Fourth Affiliated Hospital of the China Medical University, No. 4 Chongshan Road, Shenyang, 110032, China.
Dewei ZhangDepartment of the Third general surgery, The Fourth Affiliated Hospital of the China Medical University, No. 4 Chongshan Road, Shenyang, 110032, China. zhdeweizh@sina.com.
Yuanxin TangDepartment of the Third general surgery, The Fourth Affiliated Hospital of the China Medical University, No. 4 Chongshan Road, Shenyang, 110032, China.
China Medical University · CNFourth Affiliated Hospital of China Medical University · CNShenyang Anorectal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This meta-analysis aimed to assess the diagnostic efficiency of blood-based septin 9 (SEPT9) methylation assay for the detection of colorectal cancer (CRC). Studies were searched in the Springer, Wiley, Cochrane Library, PubMed, Ovid, Embase, Web of Science, China BioMedicine, Wanfang and China National Knowledge Infrastructure databases until July 2017. Methodological quality assessment was performed based on the guidelines of the Quality Assessment of Diagnostic Accuracy Studies. According to 1/3 and 2/3 algorithms, the meta-analyses for the diagnostic effect of SEPT9 in CRC were compared with healthy subjects and subjects with polyps, adenoma, and non-CRC, respectively. The random effects model was applied and publication bias was evaluated. The included 29 studies comprised 10,486 subjects (3202 patients with CRC and 7284 controls). In comparison with healthy subjects, the pooled sensitivity with 95% confidence intervals (CIs) of SEPT9 methylation for the diagnosis of CRC was 0.74 (95% CI: 0.61-0.84) in the 1/3 algorithm group, whereas the specificity was 0.96 (95% CI: 0.95-0.97) in the 2/3 algorithm group. Additionally, positive likelihood ratio was less than 10 and negative likelihood ratio more than 0.1 in the 2/3 algorithm group for patients with CRC vs. polyps and adenoma. The P value of Deeks' funnel plot was 0.36, suggesting that there was no publication bias. SEPT9 methylation can be used to diagnose CRC in healthy individuals under the 2/3 algorithm. The determination of SEPT9 methylation does not distinguish well between CRC and polyps or adenoma.

Indexed as

DNA MethylationGene Expression Regulation, NeoplasticAdenomaAlgorithmsBiomarkers, TumorCase-Control StudiesColorectal NeoplasmsEarly Detection of CancerHumansPrognosisSeptinsBiomarkers, TumorSEPTIN9 protein, humanSeptinsColorectal cancerNegative likelihood ratioPositive likelihood ratioSEPT9 methylationSummary receiver operating characteristic

Identifiers

PMID30488278
OpenAlexW2902949290

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.